ArticleBreast cancer research : BCR2020
Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
Erratum issuedOpen access · goldAbstract readMulticenter Study
In one paragraph
Article in Breast cancer research : BCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
9.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Association between hysterectomy, oophorectomy, and risk of breast cancer: a meta-analysis.Archives of gynecology and obstetrics · 2025Pooled it
- Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.Journal of cancer research and clinical oncology · 2021Pooled it
- Impact of Ethnicity on the Uptake of Risk Reducing Mastectomy in Unaffected BRCA1/2 and PALB2 Carriers in Canada.Annals of surgical oncology · 2026Article
- Natural menopause, menarche and breast cancer risk in BRCA1 and BRCA2 pathogenic variant carriers: a Mendelian randomization analysis.British journal of cancer · 2026Article
- Estrogen receptor-positive, BRCA1-deficient breast cancer: BRCA1-epimutated tumors presenting a piece to the puzzle.Breast cancer research : BCR · 2026Review
- Preoperative Breast MRI and Histopathology in Breast Cancer: Concordance, Challenges and Emerging Role of CEM and mpMRI.Diagnostics (Basel, Switzerland) · 2025Review
- The TESTBREAST journey: Revisiting the importance of early detection by frequent screening of women at high risk of breast cancer.International journal of cancer · 2025Article
- Breast Density Changes after Risk-Reducing Salpingo-oophorectomy in Women with a Pathogenic Germline Variant in BRCA1 or BRCA2.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Comprehensive Clinical Genetics, Molecular and Pathological Evaluation Efficiently Assist Diagnostics and Therapy Selection in Breast Cancer Patients with Hereditary Genetic Background.International journal of molecular sciences · 2024Article
- Evaluation of an Italian Population-Based Programme for Risk Assessment and Genetic Counselling and Testing for BRCA1/2-Related Hereditary Breast and Ovarian Cancer after 10 Years of Operation: An Observational Study Protocol.Methods and protocols · 2024Article
- Basic knowledge for counseling patients undergoing risk-reducing salpingo-oophorectomy.Obstetrics & gynecology science · 2024Article
- Article
- Article
- Effects of Endocrine Interventions Targeting ERα or PR on Breast Cancer Risk in the General Population and Carriers ofInternational journal of molecular sciences · 2024Review
- Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of Breast Cancer-Associated Germline Pathogenic Variants in Mexico.JCO global oncology · 2024Article
- Psychosocial outcomes after varying risk management strategies in women at increased familial breast cancer risk: a mixed methods study of patient and partner outcomes.Annals of the Royal College of Surgeons of England · 2024Article
- Prophylactic Interventions for Hereditary Breast and Ovarian Cancer Risks and Mortality in BRCA1/2 Carriers.Cancers · 2023Review
- Choices for cancer prevention for women with a BRCA1 mutation? a personal view.Hereditary cancer in clinical practice · 2023Article
- Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium.Breast cancer research : BCR · 2023Article
- Hysterectomy, bilateral oophorectomy, and breast cancer risk in a racially diverse prospective cohort study.Journal of the National Cancer Institute · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
63 authors at 20 institutions in 14 countries.
Nasim MavaddatCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, CBI 8RN, UK. nm274@medschl.cam.ac.uk.ORCID http://orcid.org/0000-0003-0307-055X
Antonis C AntoniouCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, CBI 8RN, UK.
Thea M MooijDepartment of Epidemiology, Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, Amsterdam, The Netherlands.
Maartje J HooningDepartment of Medical Oncology, Family Center Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Bernadette A Heemskerk-GerritsenDepartment of Medical Oncology, Family Center Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
GENEPSO
Catherine NoguèsDASC, Oncogénétique Clinique, Institut Paoli-Calmettes, Marseille, France.
Marion Gauthier-VillarsInstitut Curie, Service de Génétique, Paris, France.
Olivier CaronDépartement de Médecine Oncologique, Gustave Roussy Hôpital Universitaire, Villejuif, France.
Paul GestaCentre Hospitalier, Service Régional d'Oncologie Génétique Poitou-Charentes, Niort, France.
Pascal PujolUnité d'Oncogénétique, CHU Arnaud de Villeneuve, Montpellier, France.
Alain LortholaryCentre Catherine de Sienne, Service d'Oncologie Médicale, Nantes, France.
EMBRACE
Daniel BarrowdaleCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, CBI 8RN, UK.
Debra FrostCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, CBI 8RN, UK.
D Gareth EvansGenomic Medicine, Manchester Academic Health Sciences Centre, Division of Evolution and Genomic Sciences, Manchester University, Central Manchester, University Hospitals NHS Foundation Trust, Manchester, UK.
Louise IzattClinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Julian AdlardYorkshire Regional Genetics Service, Chapel Allerton Hospital and University of Leeds, Leeds, UK.
Ros EelesOncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
Carole BrewerDepartment of Clinical Genetics, Royal Devon & Exeter Hospital, Exeter, UK.
Marc TischkowitzAcademic Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
Alex HendersonInstitute of Genetic Medicine, Centre for Life, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK.
Jackie CookSheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, UK.
Diana EcclesUniversity of Southampton Faculty of Medicine, Southampton University Hospitals NHS Trust, Southampton, UK.
HEBON
Klaartje van EngelenDepartment of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Marian J E MouritsDepartment of Gynaecological Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Margreet G E M AusemsDepartment of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
Linetta B KoppertDepartment of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
John L HopperCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, 3010, Australia.
Esther M JohnDepartment of Medicine and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Wendy K ChungDepartments of Pediatrics and Medicine, Columbia University Medical Center, New York, NY, USA.
Irene L AndrulisDepartment of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Mary B DalyDepartment of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA.
Saundra S BuysDepartment of Medicine, Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT, USA.
kConFab Investigators
Javier BenitezHuman Genetics Group and Genotyping Unit, CEGEN, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Trinidad CaldesMolecular Oncology Laboratory, Hospital Clinico San Carlos, IdISSC, CIBERONC (ISCIII), Madrid, Spain.
Anna JakubowskaDepartment of Genetics and Pathology, Pomeranian Medical University, Unii Lubelskiej 1, Szczecin, Poland.
Jacques SimardGenomics Center, Centre Hospitalier Universitaire de Québec, Université Laval Research Center, 2705 Laurier Boulevard, Quebec City, Quebec, Canada.
Christian F SingerDepartment of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A 1090, Vienna, Austria.
Yen TanDepartment of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A 1090, Vienna, Austria.
Edith OlahDepartment of Molecular Genetics, National Institute of Oncology, Budapest, Hungary.
Marie NavratilovaDepartment of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Zluty kopec 7, 65653, Brno, Czech Republic.
Lenka ForetovaDepartment of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Zluty kopec 7, 65653, Brno, Czech Republic.
Anne-Marie GerdesDepartment of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Marie-José Roos-BlomDepartment of Epidemiology, Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, Amsterdam, The Netherlands.
Flora E Van LeeuwenDepartment of Epidemiology, Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, Amsterdam, The Netherlands.
Brita ArverThe Department of Oncology and Pathology, Karolinska Institute, 171 76, Stockholm, Sweden.
Håkan OlssonDepartment of Oncology, Lund University Hospital, Lund, Sweden.
Rita K SchmutzlerCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany.
Christoph EngelInstitute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
Karin KastDepartment of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Kelly-Anne PhillipsCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, 3010, Australia.
Mary Beth TerryHerbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.
Roger L MilneCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, 3010, Australia.
David E GoldgarDepartment of Dermatology, University of Utah School of Medicine, 30 North 1900 East, SOM 4B454, Salt Lake City, UT, 841232, USA.
Matti A RookusDepartment of Epidemiology, Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, Amsterdam, The Netherlands.
Nadine AndrieuINSERM, U900, Paris, France.
Douglas F EastonCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, CBI 8RN, UK.
IBCCS
kConFab
BCFR
University of Cambridge · GBThe Netherlands Cancer Institute · NLThe University of Melbourne · AUColumbia University Irving Medical Center · USErasmus MC Cancer Institute · NLLund University · SEUniversity of Utah · USCopenhagen University Hospital · DKFox Chase Cancer Center · USGuy's and St Thomas' NHS Foundation Trust · GBInserm · FRManchester Academic Health Science Centre · GBMasaryk Memorial Cancer Institute · CZRoyal Devon and Exeter Hospital · GBRoyal Marsden NHS Foundation Trust · GBSpanish National Cancer Research Centre · ESUniversity of Leeds · GBUniversity of Toronto · CAGerman Cancer Research Center · DEInstitut Curie · FR
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MBreast Cancer Family Registry CohortUM1CA164920 · NCI · CANCER PREVENTION INSTIT OF CALIFORNIA · PI ANDRULIS, IRENE, BUYS, SAUNDRA S · 2012 to 2017
$12.7MGenes, environment and breast cancer risk: The 15 year follow-up of the Prof-SC (Diversity Supplement)R01CA159868 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HOPPER, JOHN L, TERRY, MARY BETH · 2011 to 2015
$9.0MCancer Research UK 11174Cancer Research UK 16563Cancer Research UK 17523Cancer Research UK 20861Cancer Research UK 23382Cancer Research UK 26886Cancer Research UK C12292/A11174Cancer Research UK C12292/A20861Cancer Research UK C1287/23382Cancer Research UK C1287/A16563Cancer Research UK C1287/A17523NCATS NIH HHS UL1 TR001863NCI NIH HHS R01 CA159868NCI NIH HHS UM1 CA164920
Abstract
backgroundThe effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause.
methodsA multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women.
resultsThere was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar.
conclusionWe found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.
Indexed as
MutationAdultBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsCohort StudiesFemaleHumansIncidenceInternational AgenciesMenopauseMiddle AgedProspective StudiesRisk Reduction BehaviorSalpingo-oophorectomyBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCA1BRCA2Breast cancerMutationRisk-reducing salpingo-oophorectomy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.